Core Viewpoint - The company, Maiwei Biotech, announced plans to engage in foreign exchange derivative trading to mitigate risks associated with foreign exchange market fluctuations, with a total trading limit of up to $50 million or equivalent in other currencies [2] Group 1: Trading Strategy - The company and its subsidiaries intend to use self-owned funds for foreign exchange derivative trading, which includes but is not limited to foreign exchange forwards, swaps, options, and structured forwards [2] - The trading counterparties will be large domestic banks and financial institutions that are approved by regulatory authorities and have a solid credit rating [2] Group 2: Trading Limit and Duration - The total trading limit for foreign exchange derivatives is set at a maximum of $50 million [2] - The validity period for the authorized trading limit is 12 months from the date of approval by the company's board of directors, and the limit can be used in a rolling manner within this timeframe [2]